Phraction Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Phraction Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$278K	Hold	367	–	–	0.05%	63
2026 Q2	$229K	Hold	367	–	–	0.04%	61
2026 Q1	$284K	Hold	367	–	–	0.06%	59
2025 Q4	$283K	Hold	367	–	–	0.08%	60
2025 Q3	$206K	Buy	+367	New	+$208K	0.06%	66
2025 Q2	–	Sell	-367	Closed	-$233K	–	81
2025 Q1	$233K	Hold	367	–	–	0.08%	69
2024 Q4	$261K	Hold	367	–	–	0.09%	63
2024 Q3	$386K	Hold	367	–	–	0.14%	54
2024 Q2	$386K	Hold	367	–	–	0.14%	52
2024 Q1	$353K	Hold	367	–	–	0.14%	52
2023 Q4	$322K	Hold	367	–	–	0.13%	47
2023 Q3	$302K	Hold	367	–	–	0.14%	46
2023 Q2	$264K	Sell	367 -95	-21%	-$73.2K	0.13%	43
2023 Q1	$380K	Sell	462 -90	-16%	-$67.9K	0.22%	40
2022 Q4	$398K	Hold	552	–	–	0.26%	35
2022 Q3	$380K	Buy	552 +50	+10%	+$31.5K	0.29%	41
2022 Q2	$297K	Buy	+502	New	+$326K	0.2%	57

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.5B AUM 22.78% 1-Year Est. Return

GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $10.8B AUM 9.05% 1-Year Est. Return

LMCG Investments Boston, Massachusetts $1.86B AUM 40.01% 1-Year Est. Return

Phraction Management's REGN Position: Q3 2026 in Review

Phraction Management held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2026 at 367 shares worth $278K. The position accounts for 0.05% of the portfolio, ranked #63.

Phraction Management first reported a position in REGN in Q2 2022 and has held it in 17 quarters since. The position peaked at $398K in Q4 2022. 333 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Phraction Management held 367 shares of Regeneron Pharmaceuticals worth $278K as of Q3 2026.
Phraction Management left its Regeneron Pharmaceuticals share count unchanged in Q3 2026.
Regeneron Pharmaceuticals made up 0.05% of Phraction Management's portfolio in Q3 2026, its #63 holding.
Phraction Management first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
Phraction Management's Regeneron Pharmaceuticals position peaked at $398K in Q4 2022.
333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Phraction Management's 13F filing for Q3 2026, filed 14 Oct 2026.